Show simple item record

dc.contributor.authorBranford, D
dc.contributor.authorShankar, Rohit
dc.date.accessioned2022-03-07T10:44:11Z
dc.date.available2022-03-07T10:44:11Z
dc.date.issued2022-08
dc.identifier.issn0007-1250
dc.identifier.issn1472-1465
dc.identifier.otherPII S0007125022000344
dc.identifier.urihttp://hdl.handle.net/10026.1/18893
dc.description.abstract

<jats:p>The prescribing of psychotropic medications for people with an intellectual disability has changed. In many locations across England, antidepressants have become the most widely prescribed psychotropic. In the context of the current NHS England STOMP programme to reduce inappropriate psychotropic prescribing for people with intellectual disability, there is an urgent need to understand whether this change reflects evidence-based use of the medications involved. There has been little analysis into the benefits or problems associated with the change and whether it is of concern. This paper offers a variety of possible explanations and opportunities to improve clinical practice and policy.</jats:p>

dc.format.extent488-493
dc.format.mediumPrint
dc.languageen
dc.language.isoeng
dc.publisherRoyal College of Psychiatrists
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAntidepressants
dc.subjectdevelopmental disorders
dc.subjectintellectual disability
dc.subjectinformation technologies
dc.subjectpolypharmacy
dc.titleAntidepressant prescribing for adult people with an intellectual disability living in England
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000765588400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue2
plymouth.volume221
plymouth.publication-statusPublished
plymouth.journalThe British Journal of Psychiatry
dc.identifier.doi10.1192/bjp.2022.34
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeEngland
dc.identifier.eissn1472-1465
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1192/bjp.2022.34
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV